# A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

> **NCT06646289** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 24 (actual)

## Conditions studied

- X-Linked Retinitis Pigmentosa

## Interventions

- **BIOLOGICAL:** AAV5-hRKp.RPGR
- **OTHER:** No intervention (Follow-Up assessment)

## Key facts

- **NCT ID:** NCT06646289
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2030-10-24
- **Final completion:** 2030-10-24
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06646289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06646289, "A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06646289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*